RA
SPRY icon

Royce & Associates’s ARS Pharmaceuticals SPRY Stock Holding History

Royce & Associates’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$434K Sell
54,024
-153,027
-74% -$1.47M ﹤0.01% 717
2025
Q4 		$2.41M Buy
+207,051
New +$2.01M 0.02% 570
2025
Q3 		– Sell
-256,269
Closed -$4.47M – 826
2025
Q2 		$4.47M Sell
256,269
-386,497
-60% -$5.58M 0.05% 484
2025
Q1 		$8.09M Sell
642,766
-286,847
-31% -$3.45M 0.09% 339
2024
Q4 		$9.81M Buy
929,613
+238,158
+34% +$3.34M 0.09% 327
2024
Q3 		$10M Buy
691,455
+45,755
+7% +$544K 0.09% 319
2024
Q2 		$5.49M Buy
645,700
+87,000
+16% +$772K 0.05% 455
2024
Q1 		$5.71M Buy
558,700
+85,000
+18% +$634K 0.05% 466
2023
Q4 		$2.6M Buy
473,700
+10,000
+2% +$43.8K 0.02% 613
2023
Q3 		$1.75M Hold
463,700
– – 0.02% 663
2023
Q2 		$3.11M Buy
463,700
+159,800
+53% +$1.07M 0.03% 596
2023
Q1 		$1.98M Buy
+303,900
New +$2.33M 0.02% 656

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Royce & Associates's SPRY Position: Q1 2026 in Review

Royce & Associates reduced its ARS Pharmaceuticals (SPRY) stake by 74% in Q1 2026, selling an estimated $1.47M and leaving 54,024 shares worth $434K. The position accounts for ﹤0.01% of the portfolio, ranked #717.

Royce & Associates first reported a position in SPRY in Q1 2023 and has held it in 12 quarters since. The position peaked at $10M in Q3 2024. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Royce & Associates held 54,024 shares of ARS Pharmaceuticals worth $434K as of Q1 2026.
  • Royce & Associates sold 153,027 ARS Pharmaceuticals shares in Q1 2026, an estimated $1.47M.
  • ARS Pharmaceuticals made up ﹤0.01% of Royce & Associates's portfolio in Q1 2026, its #717 holding.
  • Royce & Associates first reported a position in ARS Pharmaceuticals in Q1 2023 and has held it in 12 quarters since.
  • Royce & Associates's ARS Pharmaceuticals position peaked at $10M in Q3 2024.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Royce & Associates's 13F filing for Q1 2026, filed 12 May 2026.